These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 18314273)

  • 1. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
    Alerte TN; Akinfolarin AA; Friedrich EE; Mader SA; Hong CS; Perez RG
    Neurosci Lett; 2008 Apr; 435(1):24-9. PubMed ID: 18314273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
    Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.
    Lou H; Montoya SE; Alerte TN; Wang J; Wu J; Peng X; Hong CS; Friedrich EE; Mader SA; Pedersen CJ; Marcus BS; McCormack AL; Di Monte DA; Daubner SC; Perez RG
    J Biol Chem; 2010 Jun; 285(23):17648-61. PubMed ID: 20356833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.
    Tehranian R; Montoya SE; Van Laar AD; Hastings TG; Perez RG
    J Neurochem; 2006 Nov; 99(4):1188-96. PubMed ID: 16981894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
    Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
    J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene.
    Gao N; Li YH; Li X; Yu S; Fu GL; Chen B
    Neurosci Bull; 2007 Jan; 23(1):53-7. PubMed ID: 17592526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
    Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW
    J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
    Waxman EA; Giasson BI
    J Neuropathol Exp Neurol; 2008 May; 67(5):402-16. PubMed ID: 18451726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.